Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of SCD411 versus Eylea in neovascular age-related macular degeneration
MOH_2020-08-03_009112Phase 3Not yet recruiting
- Sponsor
- Sam Chun Dang Pharm Co., Ltd.
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing SCD411 with Eylea (2 arms). Primary endpoint: Equivalence in best-corrected visual acuity at Week 8. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
SCD411aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2020-08-03_009112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-03_009112.